Reported 1 day ago
Needham has reiterated its Buy rating for Geron Corporation (NASDAQ:GERN), setting a price target of $5 after the company reported second-quarter results for 2025, where RYTELO net product revenue reached $49 million, a 24% increase from the previous quarter. Demand for RYTELO saw a significant rise of 17%. Additionally, Harout Semerjian was appointed as the new CEO, adding to the positive outlook for the company focused on therapies for blood cancers.
Source: YAHOO